Kenneth Galbraith - 05 Jan 2023 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Role
Chair & CEO, Director
Signature
/s/ Daniel Dex, Attorney-in-Fact
Issuer symbol
ZYME
Transactions as of
05 Jan 2023
Net transactions value
$0
Form type
4
Filing time
06 Jan 2023, 19:00:21 UTC
Previous filing
23 Dec 2022
Next filing
08 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Stock Option (Right to Buy) Award $0 +215,000 $0.000000 215,000 05 Jan 2023 Common Stock 215,000 $8.00 Direct F1
transaction ZYME Restricted Stock Unit Award $0 +143,000 $0.000000 143,000 05 Jan 2023 Common Stock 143,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
F2 Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F3 The RSUs vest in three equal annual installments beginning on January 5, 2024.